Login / Signup

Clinical relevant pancreatic fistula after pancreatoduodenectomy: when negative amylase levels tell the truth.

Francesco GiovinazzoRalph LinnemanGiulio Valentino Dalla RivaDaniele GreenerChristopher MoranoGijs A PatijnMark G H BesselinkVincent B NieuwenhuijsMohammad Abu Hilalnull nullI H de HinghG KazemierS FestenK P de JongC H J van EijckJ J G ScheepersM van der KolkM den DulkK BosschaD BoermaE van der HarstT ArmstrongA TakharZaed Hamady
Published in: Updates in surgery (2021)
Drain Amylase level are routinely determined to diagnose pancreatic fistula after Pancreatocoduodenectomy. Consensus is lacking regarding the cut-off value of amylase to diagnosis clinically relevant postoperative pancreatic fistulae (POPF). The present study proposes a model based on Amylase Value in the Drain (AVD) measured in the first three postoperative days to predict a POPF. Amylase cut-offs were selected from a previous published systematic review and the accuracy were validated in a multicentre database from 12 centres in 2 countries. The present study defined POPF the 2016 ISGPS criteria (3 times the upper limit of normal serum amylase). A learning machine method was used to correlate AVD with the diagnosis of POPF. Overall, 454 (27%) of 1638 patients developed POPF. Machine learning excluded a clinically relevant postoperative pancreatic fistulae with an AUC of 0.962 (95% CI 0.940-0.984) in the first five postoperative days. An AVD at a cut-off of 270 U/L in 2 days in the first three postoperative days excluded a POPF with an AUC of 0.869 (CI 0.81-0.90, p < 0.0001). A single AVD in the first three postoperative days may not exclude POPF after pancreatoduodenectomy. The levels should be monitored until day 3 and have two negative values before removing the drain. In the group with a positive level, the drain should be kept in and AVD monitored until postoperative day five.
Keyphrases
  • patients undergoing
  • systematic review
  • machine learning
  • end stage renal disease
  • clinical trial
  • chronic kidney disease
  • ejection fraction
  • randomized controlled trial
  • clinical practice
  • peritoneal dialysis